VIP36’s Mouse Dose Separation Was Not a Human Cannabis Safety Margin

Illustration of a printed chromatogram beside a sample vial and pen

VIP36 showed substantial separation between pain-related efficacy and selected central side effects in mice. The reported separation was an experimental compound-specific result, not a safety ratio for THC products.

Molecular design and animal testing

Researchers designed a charged synthetic CB1 agonist to engage a receptor pocket while limiting brain penetration and arrestin recruitment. Structural, cellular and computational methods were combined with several mouse pain models. VIP36 is not THC or cannabis.

The repeated-treatment result was favorable

The compound retained anti-allodynic efficacy through the tested nerve-injury regimen and showed limited tolerance. Selected central adverse-effect measures required much higher doses than pain-related activity. These observations supported further development of the design strategy.

The denominator matters

A dose separation depends on the efficacy endpoint, adverse-effect endpoint, route and species. It cannot establish an equivalent margin for cognition, respiratory effects, every organ system or human dosing. Reduced arrestin recruitment was a proposed contributor to the favorable profile, not proof that this pathway alone explains every outcome. The study demonstrates a targeted drug-development approach while leaving clinical efficacy, exposure and safety to future patient research.

Related analysis: A Peripheral Cannabinoid Label Did Not Guarantee Freedom From Central Effects.

Primary research

A cryptic pocket in CB1 drives peripheral and functional selectivity. Nature (2025). DOI: 10.1038/s41586-025-08618-7.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

What Did Mental Health Professionals Report After a Breathwork Workshop?

Ulrike Lueken and colleagues asked 48 mental health professionals to take part in a high-ventilation breathwork workshop and rate their experience. The participants reported altered states and also gave their judgments about possible therapeutic uses and risks. Those ratings describe the views of the workshop group. They do not measure…

Spread the love

Read Article: What Did Mental Health Professionals Report After a Breathwork Workshop?

What Changed on an Emotional Face Recognition Task After Psilocybin With Support?

In an open-label study, J. B. Stroud and colleagues found that people with treatment-resistant depression recognized facial emotions faster one month after receiving psilocybin with psychological support. Seventeen patients completed the task at baseline and follow-up. Sixteen untreated controls completed it on the same schedule. The researchers reported a group-by-time…

Spread the love

Read Article: What Changed on an Emotional Face Recognition Task After Psilocybin With Support?

What Did a Young-Adult CBD Survey Reveal About How Users Chose a Dose?

A survey of young adults asked how CBD users chose a dose. Their answers show why a product history needs more detail than a report of CBD use.

Spread the love

Read Article: What Did a Young-Adult CBD Survey Reveal About How Users Chose a Dose?

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us